New House Oversight Panel Chairman Towns Less Combative With Industry
This article was originally published in The Tan Sheet
Executive Summary
Drug companies likely will face less combative investigations into their activities by the House Oversight and Government Reform Committee during the 111th Congress
You may also be interested in...
FDA Feels Heat Alongside J&J As House Oversight Investigates OTC Recall
FDA finds itself under congressional scrutiny alongside Johnson & Johnson even as the agency investigates and weighs possible enforcement against J&J following the firm's third OTC recall in eight months
FDA Feels Heat Alongside J&J As House Oversight Investigates OTC Recall
FDA finds itself under congressional scrutiny alongside Johnson & Johnson even as the agency investigates and weighs possible enforcement against J&J following the firm's third OTC recall in eight months
FDA Feels Heat Alongside J&J As House Oversight Investigates OTC Recall
FDA finds itself under congressional scrutiny alongside Johnson & Johnson even as the agency investigates and weighs possible enforcement against J&J following the firm's third OTC recall in eight months